A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

NCT02965053 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperphosphatemia

Interventions

DRUG: EOS789
DRUG: Placebo
DRUG: Renvela

Sponsor

Chugai Pharmaceutical